The long-term control of tuberculosis (TB) will require the development of more effective anti-TB vaccines, as the only licensed vaccine, Mycobacterium bovis bacille Calmette-Guérin (BCG), has limited protective efficacy against infectious pulmonary TB. Subunit vaccines have an improved safety profile over live, attenuated vaccines, such as BCG, and may be used in immuno-compromised individuals. MPT83 (Rv2873) is a secreted mycobacterial lipoprotein expressed on the surface of Mycobacterium tuberculosis. In this study, we examined whether recombinant MPT83 is recognized during human and murine M. tuberculosis infection. We assessed the immunogenicity and protective efficacy of MPT83 as a protein vaccine, with monophosphyl lipid A (MPLA) in dimethyl-dioctadecyl ammonium bromide (DDA) as adjuvant, or as a DNA vaccine in C57BL/6 mice and mapped the T cell epitopes with peptide scanning. We demonstrated that rMPT83 was recognised by strong proliferative and Interferon (IFN)-γ-secreting T cell responses in peripheral blood mononuclear cells (PBMC) from patients with active TB, but not from healthy, tuberculin skin test-negative control subjects. MPT83 also stimulated strong IFN-γ T cell responses during experimental murine M. tuberculosis infection. Immunization with either rMPT83 in MPLA/DDA or DNA-MPT83 stimulated antigen-specific T cell responses, and we identified MPT83127–135 (PTNAAFDKL) as the dominant H-2b-restricted CD8+ T cell epitope within MPT83. Further, immunization of C57BL/6 mice with rMPT83/MPLA/DDA or DNA-MPT83 stimulated significant levels of protection in the lungs and spleens against aerosol challenge with M. tuberculosis. Interestingly, immunization with rMPT83 in MPLA/DDA primed for stronger IFN-γ T cell responses to the whole protein following challenge, while DNA-MPT83 primed for stronger CD8+ T cell responses to MPT83127–135. Therefore MPT83 is a protective T cell antigen commonly recognized during human M. tuberculosis infection and should be considered for inclusion in future TB subunit vaccines.
References
[1]
World Health Organization (2011) Global tuberculosis control: WHO report 2011. Geneva: World Health Organization. viii, 246 p.
[2]
Fine PE (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339–1345.
[3]
Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115: 2472–2479.
[4]
Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, et al. (2008) A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198: 1491–1501.
[5]
Dey B, Jain R, Gupta UD, Katoch VM, Ramanathan VD, et al. (2011) A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis. PLoS One 6: e23360.
[6]
Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, et al. (2005) Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23: 2740–2750.
[7]
Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, et al. (2010) Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 28: 1084–1093.
[8]
Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De Kock E, et al. (2009) The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin 5: 475–482.
[9]
McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine 10: 1240–1244.
[10]
Reed S, Lobet Y (2005) Tuberculosis vaccine development; from mouse to man. Microbes Infect 7: 922–931.
[11]
Hewinson RG, Michell SL, Russell WP, McAdam RA, Jacobs WR (1996) Molecular characterization of MPT83: a seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70. Scand J Immunol 43: 490–499.
[12]
Wiker HG, Lyashchenko KP, Aksoy AM, Lightbody KA, Pollock JM, et al. (1998) Immunochemical characterization of the MPB70/80 and MPB83 proteins of Mycobacterium bovis. Infect Immun 66: 1445–1452.
[13]
Lesellier S, Corner L, Costello E, Sleeman P, Lyashchenko K, et al. (2008) Antigen specific immunological responses of badgers (Meles meles) experimentally infected with Mycobacterium bovis. Vet Immunol Immunopathol 122: 35–45.
[14]
Cai H, Tian X, Hu XD, Li SX, Yu DH, et al. (2005) Combined DNA vaccines formulated either in DDA or in saline protect cattle from Mycobacterium bovis infection. Vaccine 23: 3887–3895.
[15]
Chambers MA, Vordermeier H, Whelan A, Commander N, Tascon R, et al. (2000) Vaccination of mice and cattle with plasmid DNA encoding the Mycobacterium bovis antigen MPB83. Clin Infect Dis 30: Suppl 3S283–287.
[16]
Vordermeier HM, Cockle PJ, Whelan AO, Rhodes S, Chambers MA, et al. (2000) Effective DNA vaccination of cattle with the mycobacterial antigens MPB83 and MPB70 does not compromise the specificity of the comparative intradermal tuberculin skin test. Vaccine 19: 1246–1255.
[17]
Chambers MA, Gavier-Widen D, Hewinson RG (2004) Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge. FEMS Immunol Med Microbiol 41: 93–100.
[18]
Charlet D, Mostowy S, Alexander D, Sit L, Wiker HG, et al. (2005) Reduced expression of antigenic proteins MPB70 and MPB83 in Mycobacterium bovis BCG strains due to a start codon mutation in sigK. Mol Microbiol 56: 1302–1313.
[19]
Kaufmann SH, Hussey G, Lambert PH (2010) New vaccines for tuberculosis. Lancet 375: 2110–2119.
[20]
Aagaard C, Dietrich J, Doherty M, Andersen P (2009) TB vaccines: current status and future perspectives. Immunol Cell Biol 87: 279–286.
[21]
van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, et al. (2010) Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 28: 3571–3581.
[22]
Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, et al. (2009) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 179: 724–733.
[23]
Wiker HG, Harboe M, Nagai S (1991) A localization index for distinction between extracellular and intracellular antigens of Mycobacterium tuberculosis. J Gen Microbiol 137: 875–884.
[24]
Malen H, Berven FS, Softeland T, Arntzen MO, D’Santos CS, et al. (2008) Membrane and membrane-associated proteins in Triton X-114 extracts of Mycobacterium bovis BCG identified using a combination of gel-based and gel-free fractionation strategies. Proteomics 8: 1859–1870.
[25]
Harboe M, Wiker HG, Ulvund G, Lund-Pedersen B, Andersen AB, et al. (1998) MPB70 and MPB83 as indicators of protein localization in mycobacterial cells. Infect Immun 66: 289–296.
[26]
Green LR, Jones CC, Sherwood AL, Garkavi IV, Cangelosi GA, et al. (2009) Single-antigen serological testing for bovine tuberculosis. Clin Vaccine Immunol 16: 1309–1313.
[27]
Whelan AO, Clifford D, Upadhyay B, Breadon EL, McNair J, et al. (2010) Development of a skin test for bovine tuberculosis for differentiating infected from vaccinated animals. J Clin Microbiol 48: 3176–3181.
[28]
Goodger J, Nolan A, Russell WP, Dalley DJ, Thorns CJ, et al. (1994) Serodiagnosis of Mycobacterium bovis infection in badgers: development of an indirect ELISA using a 25 kDa antigen. Vet Rec 135: 82–85.
[29]
Said-Salim B, Mostowy S, Kristof AS, Behr MA (2006) Mutations in Mycobacterium tuberculosis Rv0444c, the gene encoding anti-SigK, explain high level expression of MPB70 and MPB83 in Mycobacterium bovis. Mol Microbiol 62: 1251–1263.
[30]
Mustafa AS (2011) Comparative evaluation of MPT83 (Rv2873) for T helper-1 cell reactivity and identification of HLA-promiscuous peptides in Mycobacterium bovis BCG-vaccinated healthy subjects. Clin Vaccine Immunol 18: 1752–1759.
[31]
Xue T, Stavropoulos E, Yang M, Ragno S, Vordermeier M, et al. (2004) RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection. Infect Immun 72: 6324–6329.
[32]
van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P (2000) Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 30: 3689–3698.
[33]
Nambiar JK, Ryan AA, Kong CU, Britton WJ, Triccas JA (2010) Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. Eur J Immunol 40: 153–161.
[34]
Morris S, Kelley C, Howard A, Li Z, Collins F (2000) The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 18: 2155–2163.
[35]
Cai H, Yu DH, Tian X, Zhu YX (2005) Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA Cell Biol 24: 605–613.
[36]
Chambers MA, Williams A, Hatch G, Gavier-Widen D, Hall G, et al. (2002) Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis. Infect Immun 70: 2159–2165.
[37]
Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, et al. (2011) In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6: e19252.
[38]
Sardesai NY, Weiner DB (2011) Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 23: 421–429.
[39]
Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69: 2773–2778.
[40]
Aagaard C, Hoang TT, Izzo A, Billeskov R, Troudt J, et al. (2009) Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One 4: e5930.
[41]
Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, et al. (2007) The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25: 14–18.
[42]
Derrick SC, Yang AL, Morris SL (2004) A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 23: 780–788.
[43]
Feng CG, Palendira U, Demangel C, Spratt JM, Malin AS, et al. (2001) Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. Infect Immun 69: 4174–4176.
[44]
Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, et al. (2011) The TLR4 Agonist Monophosphoryl Lipid A Augments Innate Host Resistance to Systemic Bacterial Infection. Infect Immun.
[45]
Werninghaus K, Babiak A, Gross O, Holscher C, Dietrich H, et al. (2009) Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 206: 89–97.
[46]
Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, et al. (2010) Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 184: 2756–2760.
[47]
Henriksen-Lacey M, Devitt A, Perrie Y (2011) The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release.
[48]
West NP, Wozniak TM, Valenzuela J, Feng CG, Sher A, et al. (2008) Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis. Vaccine 26: 3853–3859.
[49]
Shanahan ER, Pinto R, Triccas JA, Britton WJ, West NP (2010) Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine. Vaccine 28: 1341–1346.
